<DOC>
	<DOCNO>NCT02947152</DOCNO>
	<brief_summary>A first-in-human study use HKT288 solid tumor , include epithelial ovarian cancer renal cell carcinoma</brief_summary>
	<brief_title>HKT288 Solid Tumors , Including Epithelial Ovarian Cancer Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<criteria>Advanced ( metastatic locally advance ) serous epithelial ovarian , serous fallopian tubal serous primary peritoneal cancer advance clear cell papillary renal cell carcinoma receive intolerant therapy know confer clinical benefit disease , determine investigator . Tumor sample available retrospective CDH6 expression test Eastern Cooperative Oncology Group ( ECOG ) Performance status ≤2 Patient active chronic corneal disorder Patients monocular vision medium opacity condition precludes monitor retina fundus . Patients history serious allergic reaction Patients QTcF &gt; 470 msec screen ECG congenital long QT syndrome Any prior history treatment maytansine ( DM1 DM4 ) base ADC Patient receive anticancer therapy within follow time frame prior first dose study treatment : Conventional cytotoxic chemotherapy : ≤4 week ( ≤ 6 week nitrosoureas mitomycinC ) Biologic therapy ( e.g. , antibody ) : ≤4 week Noncytotoxic small molecule therapeutic : ≤5 halflives ≤2 week ( whichever longer ) Other investigational agent : ≤4 week Radiation therapy ( except localize radiotherapy analgesic purpose lytic lesion risk fracture ) : ≤4 week Radiation therapy ( localized radiotherapy analgesic purpose lytic lesion risk fracture ) ≤2 week Major surgery : ≤2 week Other protocol define inclusion/exclusion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>HKT288</keyword>
	<keyword>CDH6</keyword>
	<keyword>ADC</keyword>
	<keyword>maytansine</keyword>
	<keyword>epithelial ovarian cancer</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>RCC</keyword>
</DOC>